Physician
Guzman, Maurice
Guzman, Maurice was paid $1.36M by Medicaid between Jan 2018 and Dec 2024, across 35 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 32% of everything it billed.
33Billing provider infoGUZMAN, MAURICE
CHICAGO, IL 60629
CHICAGO, IL 60629
33aNPI1528057874assigned 10/19/2005
33bProvider typeFamily Medicine Physician
28Total paid$1.36M
24GClaims28,792
24DCodes billed35
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Illinois
Rank by total paid#71 of 2,947
Median peer was paid$43K
This provider vs. median32×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,936 | $87K | |
| 2019 | 2,317 | $97K | |
| 2020 | 2,187 | $102K | |
| 2021 | 2,576 | $124K | |
| 2022 | 8,892 | $389K | |
| 2023 | 6,529 | $324K | |
| 2024incomplete | 4,355 | $235K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 32% | 9,273 | 7,727 | $430K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 29% | 5,731 | 4,869 | $397K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 11% | 2,036 | 1,707 | $151K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 7.5% | 2,526 | 2,211 | $102K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.8% | 2,212 | 1,908 | $51K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.6% | 1,987 | 1,733 | $49K |
| 87631 | 2.5% | 336 | 317 | $34K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.2% | 82 | 82 | $30K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.8% | 285 | 271 | $24K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.2% | 49 | 45 | $17K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 331 | 319 | $16K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 161 | 147 | $12K |
23 more codes
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 142 | $12K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 120 | $10K |
| 90756 | <1% | 211 | $5K | |
| 82962 | <1% | 2,127 | $4K | |
| 87641 | <1% | 53 | $2K | |
| 87486 | <1% | 53 | $2K | |
| 87581 | <1% | 53 | $2K | |
| 90661 | <1% | 74 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 68 | $2K |
| 87529 | <1% | 13 | $904.78 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 178 | $480.35 |
| 90686 | <1% | 50 | $454.76 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13 | $452.37 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13 | $452.37 |
| 86580 | <1% | 110 | $440.00 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 13 | $370.24 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 32 | $358.90 |
| 90674 | <1% | 16 | $298.50 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 16 | $251.20 |
| 90619 | <1% | 13 | $217.23 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 381 | $213.70 |
| 99406 | <1% | 19 | $127.50 | |
| 90734 | <1% | 15 | $96.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.